Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Management: Real-World Evaluation in Bangladesh
Author: Amin et al. Summary: The escalating global prevalence of type 2 diabetes mellitus (T2DM) with its associated healthcare burden necessitate the innovation of effective and adaptable treatment approaches. Omarigliptin, a once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, has been demonstrated with promising outcomes in the management of T2DM in clinical trials conducted across the world. This study aims to assess the real-world effectiveness and safety of omarigliptin in the management of newly diagnosed T2DM clinical settings in Bangladesh. This observational study will be conducted at BIRDEM General Hospital in Bangladesh over a period of 12 months. Individuals aged 18 years or
Comparison of fasting and random lipid profiles among subjects with type 2 diabetes mellitus: an outpatient-based cross-sectional study in Bangladesh
Author: Kamrul-Hasan et al. Summary: Despite the wide acceptability of fasting lipid profiles in practice, emerging evidence suggests that random lipid profiles might be a convenient alternative for lipid measurement. The objective of the present study was to compare the fasting and random lipid profile among subjects with type 2 diabetes mellitus (T2DM). The present cross-sectional study included 1543 subjects with T2DM visiting several endocrinology outpatient clinics throughout Bangladesh from January to December 2021. The fasting lipid profile was measured in the morning following 8–10 h of overnight fasting, and the random lipid profile was measured at any time of the